Asthma is a common chronic inflammatory condition of the airways that affects about 350
million people globally. In 5%–10% of individuals, it is severe, with considerable morbidity …

Severe asthma is a heterogeneous disease with different phenotypes based on clinical,
functional or inflammatory parameters. In particular, the eosinophilic phenotype is …

Rationale: Tezepelumab reduced exacerbations in patients with severe, uncontrolled
asthma across a range of baseline blood eosinophil counts and fractional exhaled nitric …

Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with
severe eosinophilic asthma is needed to assess whether the data from randomised …

Introduction Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was
demonstrated in randomised controlled trials; data on its real-world impact in routine clinical …

Background The comparative safety and efficacy of the biologics currently approved for
asthma are unclear. Objective We compared the safety and efficacy of mepolizumab …

Monoclonal antibodies targeting interleukin (IL)-5 pathways have revolutionized the
treatment expectations for eosinophilic-associated conditions, particularly in patients with …

Galectin-10 is a member of the lectin family and one of the most abundant cytoplasmic
proteins in human eosinophils. Except for some myeloid leukemia cells, basophils, and …

In recent years, major developments have occurred in severe asthma management.
Different asthma phenotypes and subgroups have been identified and new treatment …

Asthma is a common and burdensome chronic inflammatory airway disease that affects both
children and adults. One of the main concerns with asthma is the manifestation of …